FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209884920> ?p ?o ?g. }

• W3209884920 endingPage "S26" @default.
• W3209884920 startingPage "S26" @default.
• W3209884920 abstract "The usage of topical TXA has been shown in certain cases of epistaxis to reduced time to stop bleeding, rates of rebleeding, time spent in the emergency department and increased patient satisfaction. Local administration of topical TXA has since been described in various settings in emergency medicine journals. This study seeks to evaluate the use of tranexamic acid as a medication for the management of epistaxis and other superficial hemorrhages in the emergency department (ED) of local community hospitals. Retrospective review of adult ED patients from two community hospitals presenting with epistaxis or other superficial hemorrhage, treated with topical tranexamic acid (TXA) and discharged home between 2016 and 2019. Excluded from the study are traumatic nose injuries, major trauma patients, post-operative patients, and patients with incomplete data. Abstracted data included demographics, chief complaints, discharge diagnosis, history of anticoagulant use, outcome of TXA use, and 72 hours return to the ED with recurrent hemorrhage. Data analysis was performed on the index cases only. Demographics and outcomes are reported as descriptive statistics. Significance is set at 0.05 for comparison between anti-coagulation groups. There were 341 cases meeting inclusion criteria. Ten cases were excluded with four nasal trauma, three post-operative cases, and three with missing data. Nineteen case were patients returning within 72 hours, leaving 312 index cases. There were 192 cases of epistaxis and 120 cases of cutaneous (81) or mucosal (39) wounds. Overall, 48.4% of the patients were on outpatient anti-coagulants with 7.7% on two medications. The 72-hour return rate was 5.8% with 6.8% in the epistaxis group and 4.2% in the superficial wound group. Outpatient anti- coagulation did not affect 72 hours returns in epistaxis (6.5% versus 7.1%; p=0.856) but was significant in superficial wounds (11.6% return in anti-coagulant group versus 0%; p=0.002). In this four-year study of topical tranexamic acid use in two community emergency departments, 48.4% of the patients were on outpatient anti-coagulants. The 72-hour return rate for epistaxis was 6.8% and not affected by anti-coagulant use while the return rate for superficial wounds was 4.2% and impacted by anti-coagulant use. Epistaxis and superficial wound treated in the emergency department with topical tranexamic acid have a small return rate for hemorrhage control, despite outpatient anti-coagulant use.View Large Image Figure ViewerDownload Hi-res image Download (PPT)" @default.
• W3209884920 created "2021-11-08" @default.
• W3209884920 creator A5015485647 @default.
• W3209884920 creator A5034226944 @default.
• W3209884920 creator A5054804732 @default.
• W3209884920 creator A5084909969 @default.
• W3209884920 date "2021-10-01" @default.
• W3209884920 modified "2023-09-26" @default.
• W3209884920 title "63 Topical Use of Tranexamic Acid in the Emergency Department" @default.
• W3209884920 doi "https://doi.org/10.1016/j.annemergmed.2021.09.072" @default.
• W3209884920 hasPublicationYear "2021" @default.
• W3209884920 type Work @default.
• W3209884920 sameAs 3209884920 @default.
• W3209884920 citedByCount "0" @default.
• W3209884920 crossrefType "journal-article" @default.
• W3209884920 hasAuthorship W3209884920A5015485647 @default.
• W3209884920 hasAuthorship W3209884920A5034226944 @default.
• W3209884920 hasAuthorship W3209884920A5054804732 @default.
• W3209884920 hasAuthorship W3209884920A5084909969 @default.
• W3209884920 hasBestOaLocation W32098849201 @default.
• W3209884920 hasConcept C118552586 @default.
• W3209884920 hasConcept C141071460 @default.
• W3209884920 hasConcept C144024400 @default.
• W3209884920 hasConcept C149923435 @default.
• W3209884920 hasConcept C167135981 @default.
• W3209884920 hasConcept C194828623 @default.
• W3209884920 hasConcept C2779637338 @default.
• W3209884920 hasConcept C2780084366 @default.
• W3209884920 hasConcept C2780724011 @default.
• W3209884920 hasConcept C2991743468 @default.
• W3209884920 hasConcept C71924100 @default.
• W3209884920 hasConceptScore W3209884920C118552586 @default.
• W3209884920 hasConceptScore W3209884920C141071460 @default.
• W3209884920 hasConceptScore W3209884920C144024400 @default.
• W3209884920 hasConceptScore W3209884920C149923435 @default.
• W3209884920 hasConceptScore W3209884920C167135981 @default.
• W3209884920 hasConceptScore W3209884920C194828623 @default.
• W3209884920 hasConceptScore W3209884920C2779637338 @default.
• W3209884920 hasConceptScore W3209884920C2780084366 @default.
• W3209884920 hasConceptScore W3209884920C2780724011 @default.
• W3209884920 hasConceptScore W3209884920C2991743468 @default.
• W3209884920 hasConceptScore W3209884920C71924100 @default.
• W3209884920 hasIssue "4" @default.
• W3209884920 hasLocation W32098849201 @default.
• W3209884920 hasOpenAccess W3209884920 @default.
• W3209884920 hasPrimaryLocation W32098849201 @default.
• W3209884920 hasRelatedWork W1533727747 @default.
• W3209884920 hasRelatedWork W1971634524 @default.
• W3209884920 hasRelatedWork W1992980926 @default.
• W3209884920 hasRelatedWork W2026035627 @default.
• W3209884920 hasRelatedWork W2092890176 @default.
• W3209884920 hasRelatedWork W2510700473 @default.
• W3209884920 hasRelatedWork W2621565100 @default.
• W3209884920 hasRelatedWork W2787439413 @default.
• W3209884920 hasRelatedWork W3154944956 @default.
• W3209884920 hasRelatedWork W3160436178 @default.
• W3209884920 hasVolume "78" @default.
• W3209884920 isParatext "false" @default.
• W3209884920 isRetracted "false" @default.
• W3209884920 magId "3209884920" @default.
• W3209884920 workType "article" @default.